Baculovirus Expression System Market Set for Significant Expansion Driven by Biopharmaceutical Demand and Advances in Protein Production

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Baculovirus Expression System Market- (By Product Type (Baculovirus, Expression Vector, Reagents, Others), By Application (Therapeutics, Vaccines, Protein Purification, Others), By End User (Biopharmaceutical Companies, Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Baculovirus Expression System Market is valued at USD 374.79 Mn in 2023, and it is expected to reach USD 660.97 Mn by the year 2031, with a CAGR of 7.43% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2227

The Baculovirus Expression System is a highly effective and versatile biotechnological tool employed for the production of recombinant proteins, particularly in molecular biology and biotechnology. This system utilizes baculoviruses, which are viruses that primarily infect insects, to express and produce target proteins. This technology has proven invaluable for virus research and a wide range of other biotechnological applications. Baculovirus stocks are currently frozen and will be thawed shortly for further use. The increasing prevalence of chronic diseases, including cancer, autoimmune conditions, and infectious diseases, is driving the demand for innovative therapeutic proteins and vaccines. Baculovirus-based expression systems have been instrumental in the development of several successful biological treatments, including monoclonal antibodies and gene therapy vectors.

The global market for biologics and biosimilars is experiencing significant growth, as the number of biologic medicines-such as monoclonal antibodies, recombinant proteins, and cell and gene therapies-continues to rise, with many new treatments being approved for chronic disease management. Baculovirus expression technology plays a key role in the efficient manufacturing of numerous licensed and pipeline biologic therapies. Among the various insect cell lines, the Sf21 cell line, derived from the Sf9 parent cells, has gained increasing popularity. Sf21 cells provide more consistent post-translational modifications, such as glycosylation, making them particularly effective for producing high-quality proteins of varying complexity through recombinant protein expression.

List of Prominent Players in the baculovirus expression system market:
• Thermo Fisher Scientific
• Merck KGaA
• Takara Bio
• Agilent Technologies
• Oxford Expression Technologies
• Promega Corporation
• Qiagen N.V.
• Bio-Rad Laboratories
• New England Biolabs
• Genscript Biotech Corporation
• Syngene International Limited
• Sartorius AG
• Aragen Bioscience
• Vivopure
• Creative Biogene
• Absolute Antibody
• Rockland Immunochemicals
• Protein Technologies Inc.
• Proteogenix
• Virovek

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-01

Market Dynamics:
Drivers:
The increasing demand for baculovirus expression systems is primarily driven by the growing use of adeno-associated virus (AAV) and other gene therapy vectors, which are increasingly being produced using this system. The ability to efficiently produce large quantities of therapeutic gene-carrying rAAV vectors is now a reality, meeting the needs of expanding gene therapy markets. The approval of several gene therapy drugs, coupled with a strong pipeline of clinical candidates, is expected to further drive demand for viral vectors, thereby accelerating the adoption of the baculovirus expression platform. Additionally, the cost-effectiveness and time efficiency of baculovirus-based production for gene therapies are attracting substantial investments from industry leaders, further fueling market growth.

Challenges:
Key challenges facing the baculovirus expression system include high production costs, a shortage of skilled professionals, and a lack of established standards and protocols. The use of live baculoviruses and serum-containing media increases the risk of contamination by adventitious viruses and prions, potentially jeopardizing human health and leading to product rejection. This increases the risk of waste of valuable reagents and bioprocessing components. Although biosafety measures such as serum-free systems can mitigate these risks, achieving high-yield expression of multiple proteins remains a challenge, which may limit the applicability of the system for certain protein drugs. The COVID-19 pandemic underscored the need for rapid, scalable manufacturing platforms for vaccines and treatments. Baculovirus-insect cell technology presents an opportunity to quickly produce vaccine antigens, which could be critical in responding to future pandemics.

Regional Trends:
The North American baculovirus expression system market is expected to capture a significant revenue share, with strong growth projected in the near term. This growth is driven by the rising production and approval of biologics such as monoclonal antibodies, recombinant proteins, and cell and gene therapies, particularly for chronic disease treatment. Furthermore, increased investment in life sciences research and development by government agencies, academic institutions, and biopharmaceutical companies is accelerating drug development and expanding market opportunities. Europe also holds a considerable share of the market, benefiting from the region's expanding pharmaceutical and biotechnology sectors, which are driving demand for recombinant proteins.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2227

Recent Developments:
• In March 2022, ProteoGenix declared the introduction of the XtenCHOTM Transient Expression System. The novel proprietary expression host based on mammalian cells obtained up to ten times greater yields with reduced manual labour in comparison to established alternatives; this was due to the optimized metabolism and enhanced stability of the plasmid. With the new CHO host, recombinant protein synthesis was intended to be simplified, and early-phase drug screening accelerated.

Segmentation of Baculovirus Expression System Market-
By Product Type-
• Baculovirus
• Expression Vector
• Reagents
• Others
By Application-
• Therapeutics
• Vaccines
• Protein Purification
• Others
By End User-
• Biopharmaceutical Companies
• Research Institutes
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/baculovirus-expression-system-market/2227

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.